Updated results of a phase 1, firstin-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM)

Category Primary study
JournalJournal of Clinical Oncology
Year 2021
This article has no abstract
Epistemonikos ID: ce64929503b88488ce9a5f65092a94c287c26ffb
First added on: Feb 13, 2025